-
Mashup Score: 2Practical strategies for creating diversity, equity, inclusion, and access in cancer clinical research: DRIVE - 1 year(s) ago
TO THE EDITOR:
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Finding a mate for MLCK: improving the potential for therapeutic targeting of gut permeability - 1 year(s) ago
Elevated intestinal permeability has long been appreciated as a pathophysiological marker of gut inflammatory disease, in particular in inflammatory bowel disease (IBD). In addition to the association of IBD risk genetic variants with multiple aspects of intestinal permeability and barrier dysfunction, increased permeability has been identified as a predictor of IBD onset in healthy first-degree…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0DOACs for VTE in patients with brain cancer and brain metastases: choices, choices, choices - 1 year(s) ago
TO THE EDITOR:
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0What Have Mechanistic Studies Taught Us About Childhood Asthma? - 1 year(s) ago
Childhood asthma is a chronic heterogeneous syndrome consisting of different disease entities or phenotypes. The immunologic and cellular processes that occur during asthma development are still not fully understood but represent distinct endotypes. Mechanistic studies have examined the role of gene expression, protein levels, and cell types in early life development and the manifestation of…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Is donor-recipient sex associated with transfusion-related outcomes in critically ill patients? - 1 year(s) ago
TO THE EDITOR:
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2JCI - Deciphering the enigma of neuroendocrine prostate cancer - 1 year(s) ago
The last two decades have seen a remarkable expansion of therapeutic options that improve survival for men with metastatic prostate cancer, yet, for most patients, these treatments ultimately lose efficacy over time (1). Many of these therapies are proficient at targeting the androgen receptor, whose signaling axis is a primary driver of cellular proliferation in prostate adenocarcinoma….
Source: www.jci.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Risk Stratification and the Art of Medicine - 2 year(s) ago
Uncertainty is inherent in patient care. Patients with cancer may especially face urgent, life-threatening complications from either the treatment or the disease, and these instances are intermixed with run-of-the-mill reasons for similar symptoms. Is abdominal pain constipation, or is it a bowel perforation? Is worsening malaise from treatment effect, a mild viral infection that will…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Given the rise in cannabis use, studies are needed to understand how it impacts cancer outcomes and identify indications for usage
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 03D-printed contact lenses: challenges towards translation and commercialization | Journal of 3D Printing in Medicine - 2 year(s) ago
Smart contact lenses are promising platforms for ocular diagnosis and treatment. Developments in microfabrication techniques and miniaturization methods played a significant role in effective control and analyses of tear fluid and/or drugs within contact lenses. Microfluidic channels, microscale probing mechanisms and reservoirs have been incorporated into contact lenses to produce wearable…
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Graft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease - 2 year(s) ago
TO THE EDITOR:
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Practical strategies for creating diversity, equity, inclusion, and access in cancer clinical research: DRIVE https://t.co/WpG53Cs6dK #commentary #healthservicesandoutcomes https://t.co/TleVg10cO7